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The 9th Bone and the Oncologist New Updates conference was held in Ottawa, Canada during 2014. This
annual meeting focuses on innovative research into the mechanisms and consequences of treatment-
induced and metastatic bone disease. Given the recent presentation of the Oxford overview's “Effects of
bisphosphonate treatment on recurrence and cause-speciﬁc mortality in women with early breast can-
cer: A meta-analysis of individual patient data from randomized trials” at the San Antonio Breast Cancer
Symposium, a debate as to the pro's and con's of adjuvant bisphosphonate use in early stage breast
cancer was undertaken. As bisphosphonate treatment in post-menopausal women appeared to de-
monstrate a similar magnitude of beneﬁt to that of other commonly used adjuvant strategies the debate
assessed whether or not there was sufﬁcient data to incorporate adjuvant bisphosphonates into standard
practice and if so, in which patient populations.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Bone and Oncologist New Updates (BONUS) meeting is an
annual conference, based in Canada that focuses on new advances in
the multidisciplinary management of cancer related bone disease. An
important goal of the meeting has been to drive research collabora-
tion within the attending audience of basic scientists and clinicians,
but also to produce guidelines and recommendations to the broader
audience of health care workers involved in the care of cancer pa-
tients. The meeting has previous produced a number of documents
covering basic science [1], translational research [2–4], clinical re-
search [5–10] and practice guidelines [11,12]. Each year a debate is
held on a controversial bone-related topic and so for the 2014 BONUS
meeting, the debate focused on the recently presented meta-analysis
by the Early Breast Cancer Trialists Collaborative Group (EBCTCG) on
the use of adjuvant bisphosphonates in early stage breast cancer [13].
Given the recognized effects of bisphosphonates in metastatic
breast cancer [14,15] and that potential anticancer effects have
been demonstrated in preclinical [16], translational [17], patients
with cancer therapy-induced bone loss [18] and population based-
studies [19,20] a number of clinical trials assessingGmbH. This is an open access art
, The Ottawa Hospital Cancer
anada, K1H8L6.bisphosphonates' effect on outcome in early stage breast cancer
have been performed. Many of these trials presented conﬂicting
results [21,24], but a consistent trend of beneﬁcial effect on breast
cancer recurrence was seen in older women. Of concern was that a
useful clinical effect might have been missed because of trial de-
sign, end-points used, and under-powering of clinical trials for
sub-group analyses [16]. Hence, an individual patient data meta
analysis was performed and presented at the San Antonio Breast
Cancer Symposium, December 2013 [13]. As this was considered
by the BONUS meeting organizers an important, but potentially
controversial topic, a debate format was used to best demonstrate
contrasting views. While the original title for the debate was “This
house believes that adjuvant bisphosphonates represent a gold-
standard for post-menopausal women with higher risk breast
cancer” the debaters asked if they could amend the title. In this
commentary, we summarize the debates ﬁndings, and incorporate
comments from the audience.2. All women with invasive breast cancer over 50 should be
offered a bisphosphonate
2.1. Presenter – Dr. Alexander Paterson
Multiple trials have studied bisphosphonates as a component
of adjuvant systemic therapy for breast cancer (Table 1). An initialicle under the CC BY-NC-ND license
Table 1
Selected larger trials of adjuvant bisphosphonates in non-metastatic breast cancer.
Trial Agent N Duration bone
agent
Outcome measure Outcome 95% CI p Summary
Powles (25) Clodronate or placebo 1069 2 years Relapse in bone (during
treatment)
HR¼0.44 0.22–0.86 0.018 Favors clodronate
Relapse in bone (follow up) HR¼0.77 0.56–1.08 0.127
Mortality (all) HR¼0.77 0.59 1.0 0.047 Favors clodronate
Mortality (Post menopausal
subgroup)
HR¼0.61 0.42–0.88 Favors clodronate
AZURE (23) Zoledronic acid or standard
care
3360 5 years DFS (all) HR¼0.94 0.82–1.06
DFS (45 years post
menopausal)
HR¼0.77 0.69–0.96 Favors zoledronic
acid
NSABP B-34 (22) Clodronate or placebo 3311 3 years DFS (all) HR¼0.91 0.78–1.07
BMFI (all) HR¼0.77 0.55–1.07 0.12
BMFI (450 years age at
entry)
HR¼0.62 0.4–0.95 0.022 Favors clodronate
OS (all) HR¼0.84 0.67–1.05 0.13
OS (450 years age at entry) HR¼0.80 0.61–1.04 0.094 Favors clodronate
Meta-analysis
(13)
Any bisphosphonate 22,982 Any duration DR (all) 22.3 versus
20.9%
0.03
DR (post menopausal) 21.9 versus
18.4%
0.0003 Favors bone agent
BC Mortality (all) 8.7 versus
16.9%
0.04
BC Mortality (post
menopausal)
18.3 versus
15.2%
0.004 Favors bone agent
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randomized 1069 patients with operable primary breast cancer to
clodronate or placebo, given for two years. The primary endpoint
of relapse in bone during the medication period showed a sig-
niﬁcant reduction in the occurrence of bone metastases in the
clodronate arm, HR 0.44 (95% CI 0.22–0.86, p¼0.016). However, for
the entire period of follow up, the reduction in occurrence of bone
metastases was non-signiﬁcant (HR 0.77, 95% CI 0.56–1.08,
p¼0.127). The secondary endpoint of mortality also showed a
signiﬁcant reduction in the clodronate arm, HR 0.77 (95% CI 0.59–
1.0, p¼0.047) with an unplanned subgroup analysis of post-me-
nopausal women showing a greater effect on mortality, with HR
0.61 (95% CI 0.42–0.88) [25].
More recently, the AZURE trial was a randomized open label
trial of standard therapy versus standard therapy and zoledronic
acid (given for ﬁve years) in 3360 women with stage II or III breast
cancer. The primary endpoint of disease free survival (DFS) did not
differ between the two groups (HR 0.94, 95% CI 0.82–1.06). How-
ever in a planned subgroup analysis, zoledronic acid improved DFS
in women who were more than 5 years since menopause at trial
entry [23]. A further similar trial, NSABP B34, randomized 3311
women with stage I–III breast cancer to oral clodronate or placebo
for three years. Again DFS did not differ between groups at a
median of 90.7 months follow up (HR 0.91, 95% CI 0.78–1.07) but
in women greater than 50 years or older at study entry, clodronate
showed beneﬁts for recurrence free interval (HR 0.75, 95% CI 0.57–
0.99, p¼0.045), bone-metastases free interval (HR 0.62, 95% CI
0.40–0.95, p¼0.027) and non-bone metastases free interval (HR
0.63, 95% CI 0.43–0.91, p¼0.014). There was no beneﬁt seen for
overall survival between the two treatment arms although there
was a numerical difference in deaths in women over 50 years of
age, favoring the clodronate arm [22].
Given these and other conﬂicting results, an individual patient
data meta-analysis was undertaken, with the results being pre-
sented at the San Antonio Breast Cancer Symposium, 2013 [13].
This analysis included 36 trials comprising 22982 patients, with
primary outcomes of time to recurrence (TTR), time to ﬁrst distant
recurrence (TFDR) and breast cancer mortality. Planned subgroup
analysis included menopausal status (if menopausal status was not
documented, women 455 years of age were considered post-menopausal). Among all women the results showed no improve-
ments in recurrence rate (26.5% no bisphosphonate versus 25.4%
bisphosphonate, p¼0.08), and a borderline improvement in dis-
tant recurrence rates (22.3% no bisphosphonate versus 20.9% bi-
sphosphonate, p¼0.03). Among the 11,036 post-menopausal wo-
men included in this analysis, signiﬁcant improvements were seen
in rates of distant recurrence (21.9% no bisphosphonate versus
18.4% bisphosphonate, po0.001) and this difference was driven by
a bisphosphonate-related reduction in bone recurrence (8.8%
versus 5.9%, po0.001). Ten-year breast cancer mortality was also
signiﬁcantly improved in post-menopausal women in the bi-
sphosphonate arm with mortality rates of 18.3% in the no bi-
sphosphonate group and 15.2% in the bisphosphonate group,
p¼0.004. This led the authors to conclude adjuvant bispho-
sphonates reduce bone metastases and improve survival in post-
menopausal women, with a 34% reduction in risk of bone recur-
rence (po0.001) and a 17% reduction in risk of breast cancer death
(p¼0.004). The effect was seen irrespective of bisphosphonate
type. There were no effects in pre-menopausal women (in parti-
cular, no deleterious effects) and no effects on non-breast cancer
deaths, contralateral breast cancer or local-regional recurrence.
In summary, this EBCCTG overview demonstrated a positive
effect from bisphosphonates in a pre-determined sub-group ana-
lysis, resulting from consistent ﬁndings from multiple well-con-
ducted trials. The ﬁnding is plausible, and the results support a
modiﬁed vicious cycle hypothesis [26,27]. The exact mechanism of
an enhanced anti-tumor effect of bisphosphonates in a low es-
trogen environment is uncertain, but certainly feasible [2,28,29].
One hypothesis may be that, by preventing enhanced bone de-
struction induced by the lack of estrogen, bisphosphonates inter-
fere with the tumor-growth-supportive functions of bone-derived
growth factors demonstrated in the vicious cycle hypothesis
[26,28]. Alternately, low estrogen levels may not be the cause,
other possibilities include increased levels of pro-inﬂammatory
proteins leading to enhanced macrophage activity in the aging
process reduced by bisphosphonates [30]. The magnitude of ben-
eﬁt of bisphosphonates is similar, if not greater than, other stra-
tegies that have been widely adopted in the breast cancer clinic.
The absolute beneﬁt in mortality for post menopausal women of
3.1% at 10 years compares to the estimated absolute beneﬁt of
Z-FAST 0.55 [0.24-1.26]
ZO-FAST 0.58 [0.34-0.99]
High Bone Turnover
Subtotal 0.74 [0.63-0.87]
0.5 1 2
Study or Group OR [95% CI]
Favours Bisphosphonate Favours No Bisphosphonate
E-ZO-FAST 1.68 [0.78-3.62]
ABCSG12 0.68 [0.50-0.92]
AZURE 0.75 [0.59-0.95]
NaTaN 0.83 [0.50-1.38]
GAIN 0.90 [0.67-1.21]
NSABP B34 0.90 [0.74-1.09]
Low Bone Turnover
Clodronate Studies 0.75 [0.47-1.20]
Subtotal 0.88 [0.76-1.03]
Fig. 1. Effect of bisphosphonate in high versus low bone turnover populations.
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sphamide, methotrexate and 5-ﬂuorouracil) of 3% at 5 years [31]
and taxanes in addition to anthracycline chemotherapy regimens,
a 3.2% gain at 8 years [32].
Further discussion presented included a rational approach as to
whom to offer bisphosphonate therapy to. Suggested populations
included; patients with osteopenia or osteoporosis, patients on
aromatase inhibitors (in whom the administration of bispho-
sphonates may ameliorate the accelerated loss of bone mineral
density seenwith aromatase inhibitors [33–35]), those with higher
risk disease (by stage, grade and receptor status). The question of
which bisphosphonate to use may be answered with the results of
the SWOG 0307 trial, that will likely be presented in 2015 [36].
Interim toxicity and patient preference results of SWOG 0307
suggest clodronate may be the preferred bisphosphonate. After
3 years of therapy, rates of osteonecrosis of the jaw were lowest
for clodronate (0.28%) compared with zoledronic acid (1.15%) and
ibandronate (0.66%), p¼0.003. Patient preference favored oral
medications at trial initiation (76% versus 24%) and this preference
changed little at the completion of therapy [37].3. Adjuvant bisphosphonates DO NOT represent a gold-stan-
dard for post-menopausal women with higher risk breast
cancer
3.1. Presenter – Dr. Eitan Amir
While the presentation of the Early Breast Cancer Trialists
Collaborative Group (EBCTCG) results [13] raises many questions it
is important to question the methodology of performing meta-
analyses. The ﬁrst point to consider is whether or not a meta-
analysis of subgroups should be used to inﬂuence clinical decision
making? Subgroup analysis have an increased probability of type I
error (false positive) when the null hypothesis is true (negative
trial). This leads to difﬁculty in interpretation. Hypotheses tested
usually address an overall treatment effect in the study population,
with no assumption of homogeneity of effect across subgroups.
The direction, not magnitude, of the treatment effect is expected
to be the same in subgroups. Stratiﬁcation or regression techni-
ques can be used to adjust the overall comparison for subgroups or
covariates. However, subgroup analyses are generally of secondary
interest and more appropriate for hypothesis generation for future
studies. If data from the EBCTCG meta analysis will be used to
change clinical practice, this will be the ﬁrst time that (pre-
dominantly unstratiﬁed) subgroup analysis has been used for de-
cision making. This is methodologically concerning as a pre-
cedence as there is a higher than desirable chance the ﬁndings are
a false positive.
In addition to the validity of a sub group analysis changing
clinical practice, the issue of patient selection was discussed. Do all
post-menopausal women beneﬁt from adjuvant bisphosphonates
or can we identify a subgroup more likely to beneﬁt? If adjuvant
bisphosphonates predominantly reduce bone metastases; are pa-
tients with higher bone turn-over more likely to develop bone
metastases? Therefore would adjuvant bisphosphonates pre-
dominantly be active in patients with higher bone turn-over? For
example, if we use the use of an adjuvant aromatase inhibitor as a
surrogate for high turnover [21,22,38–43] it appears that there is
indeed greater beneﬁt in this patient population (Fig. 1).
In summary, the quality of data to support adjuvant bispho-
sphonates in post-menopausal women should not be considered
as hypothesis testing, but rather hypothesis generating. Future
clinical trials should focus on patients with higher bone turn-over
as they appear to beneﬁt most from adjuvant bisphosphonate
therapy. Due to the above concerns, adjuvant bisphosphonates DONOT represent a gold-standard for post-menopausal women with
higher risk breast cancer.
3.2. Audience poll
Following the debate the audience were ask to vote on, “Are
adjuvant bisphosphonates now standard of care of women with
early stage breast cancer?” The majority of the audience voted no.4. Discussion
While a debate can offer a light hearted means of assessing a
particular topic it does provide an arena for opposing views to be
presented. Sadly, it is unlikely that more deﬁnitive data will an-
swer the question of whether adjuvant bisphosphonates are
standard of care for women with early stage breast cancer. The
D-CARE study [44] is evaluating the role of adjuvant denosumab
and if positive would likely lead to denosumab being the standard
of care. However, if positive in only a subgroup of patients, this will
lead further confusion to the topic. Initial results for the primary
outcome of bone metastases free survival are expected in 2016.
The SWOG 0307 trial [36], comparing adjuvant clodronate with
ibandronate and zoledronic acid, is expected to present results in
2015. While this trial may answer the question of which bispho-
sphonate is preferable, the absence of a placebo arm means that
the question of this debate will remain unclear unless one arm is
signiﬁcantly superior to the others. In addition, the results of the
SOFT [45] and TEXT [46] trials mean that increasing numbers of
premenopausal women are going to undergo ovarian suppression,
should these women also receive a bisphosphonate? To date we
are unaware of the incorporation of adjuvant bisphosphonates into
any practice guidelines but whether that changes when the
EBCTCG meta-analysis is published in peer-reviewed format re-
mains to be seen.5. Conclusion
The BONUS conference brings together physicians, scientists
and other professionals with an interest in bone health in cancer.
This year's meeting demonstrated the ever changing role of bone
targeted agents in management of patients with cancer. The
EBCTCG meta-analysis of bisphosphonate use in early breast can-
cer provides evidence for the beneﬁt of adjuvant bisphosphonate
therapy in post-menopausal women in both reducing rates of
disease recurrence and breast cancer mortality. Publication of the
data is awaited. While compelling, caution in data interpretation
C. Jacobs et al. / Journal of Bone Oncology 4 (2015) 54–58 57must be exercised as should clinical judgment and consideration
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